Nitric-oxide-mediated relaxations in salt-induced hypertension:: effect of chronic β1-selective receptor blockade

被引:51
作者
Cosentino, F
Bonetti, S
Rehorik, R
Eto, M
Werner-Felmayer, G
Volpe, M
Lüscher, TF
机构
[1] Univ Zurich Hosp, Dept Cardiol & Cardiovasc Res, CH-8091 Zurich, Switzerland
[2] IRCCS Neuromed, Pozzilli, Italy
[3] Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria
关键词
endothelial function; hypertension; nitric oxide; beta-adrenergic receptor blockade;
D O I
10.1097/00004872-200203000-00017
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Nebivolol is a new beta(1)-selective adrenergic receptor antagonist with a direct vasorelaxant effect that involves activation of the L-arginine-nitric oxide (NO) pathway. Therefore, treatment with nebivolol may protect against endothelial injury in hypertension. Objective To investigate whether chronic selective blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol. Methods Dahl salt-sensitive rats were treated for 8 weeks with standard chow or chow containing 4% NaCl alone or in combination with nebivolol (110 mg/kg per day) or atenolol (1100 mg/kg per day). Isometric tension was continuously recorded in isolated aorta and small mesenteric arteries. Constitutive NO synthase (cNOS) activity was determined by [H-3]citrulline assay. Results Chronic salt administration increased systolic blood pressure by 38 +/- 5 mmHg in salt-treated rats as compared with that in control rats. Both nebivolol and atenolol prevented a salt-induced increase in pressure. cNOS activity was significantly decreased by a high-salt diet. The impairment of endothelium-dependent relaxations in response to acetylcholine in salt-treated rats was prevented only by nebivolol, in both large and small arteries. In contrast, the reduced endothelium-independent relaxations and contractions in response to sodium nitroprusside and endothelin-1, respectively, were restored by both drugs. Nebivolol, but not atenolol, restored cNOS activity. Conclusions Despite nebivolol and atenolol having the same blood-pressure-decreasing effect, only nebivolol was able to prevent endothelial dysfunction. This study demonstrates for the first time that the acute NO-mediated vasodilatory action of nebivolol is also present during chronic treatment. Hence, nebivolol might become a new therapeutic tool with which to exert vascular protective effects against end-organ damage in conditions associated with NO deficiency. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:421 / 428
页数:8
相关论文
共 48 条
  • [1] Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries
    Altwegg, LA
    d'Uscio, LV
    Barandier, C
    Cosentino, F
    Yang, ZH
    Lüscher, TF
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 36 (03) : 316 - 320
  • [2] [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
  • [3] ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
    Barton, M
    d'Uscio, LV
    Shaw, S
    Meyer, P
    Moreau, P
    Lüscher, TF
    [J]. HYPERTENSION, 1998, 31 (01) : 499 - 504
  • [4] Barton M, 2000, J AM SOC NEPHROL, V11, P835, DOI 10.1681/ASN.V115835
  • [5] RELEASE OF ENDOTHELIN FROM THE PORCINE AORTA - INHIBITION BY ENDOTHELIUM-DERIVED NITRIC-OXIDE
    BOULANGER, C
    LUSCHER, TF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) : 587 - 590
  • [6] NITRIC-OXIDE MEDIATED VENODILATOR EFFECTS OF NEBIVOLOL
    BOWMAN, AJ
    CHEN, CPLH
    FORD, GA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (03) : 199 - 204
  • [7] Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells
    Brehm, BR
    Wolf, SC
    Bertsch, D
    Klaussner, M
    Wesselborg, S
    Schüler, S
    Schulze-Osthoff, K
    [J]. CARDIOVASCULAR RESEARCH, 2001, 49 (02) : 430 - 439
  • [8] Nebivolol:: A third-generation β-blocker that augments vascular nitric oxide release endothelial β2-adrenergic receptor-mediated nitric oxide production
    Broeders, MAW
    Doevendans, PA
    Bekkers, BCAM
    Bronsaer, R
    van Gorsel, E
    Heemskerk, JWM
    Egbrink, MGAO
    van Breda, E
    Reneman, RS
    van der Zee, R
    [J]. CIRCULATION, 2000, 102 (06) : 677 - 684
  • [9] CALVER A, 1992, J HYPERTENS, V10, P1025
  • [10] Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension
    Cardillo, C
    Kilcoyne, CM
    Quyyumi, AA
    Cannon, RO
    Panza, JA
    [J]. CIRCULATION, 1998, 97 (09) : 851 - 856